Search
Linvoseltamab
go.drugbank.com/drugs/DB17447ApprovedInvestigationalFDA in July 2025 for patients who have undergone four or more prior lines. Continued approval in the U.S. is contingent upon verification of clinical benefit in a confirmatory trial. [L53363] … [L53353] It received conditional marketing authorization in the European Union in April 2025 for patients with three or more prior lines of therapy, [L53358] and was granted accelerated approval by the
Dinutuximab
go.drugbank.com/drugs/DB09077ApprovedInvestigationalneuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. … Despite a high clinical response seen after first-line treatment, the complete eradication of neuroblastoma is rarely achieved and the majority of patients with advanced disease suffer a relapse.
Silicon
go.drugbank.com/drugs/DB12982ApprovedSilicon is under investigation in clinical trial NCT00103246 (Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or … Stage II Mycosis Fungoides).
Mixtures: Procosa II, Calcium With Mg Zn Mn Cu CR Si and Vit. C & DRespiratory Distress Syndrome
go.drugbank.com/conditions/DBCOND0027916Synonyms: Acute respiratory distress syndrome in adult or childDaxibotulinumtoxinA
go.drugbank.com/drugs/DB17929ApprovedInvestigational[A261075, L47860] DaxibotulinumtoxinA was first approved by the FDA on September 8, 2022, for the temporary improvement of glabellar lines. … It is a botulinum toxin without accessory proteins purified from the bacterium _Clostridium botulinum_ type A,[L47840] the gram-positive anaerobic bacterium primarily present in soil.
Categories: Botulinum Toxins, Type AAcetophenazine
go.drugbank.com/drugs/DB01063ApprovedIt is also used to help treat false perceptions (e.g. hallucinations or delusions). It primarily targets the dopamine D2 receptor. … Acetophenazine is an antipsychotic drug of moderate-potency. It is used in the treatment of disorganized and psychotic thinking.
Categories: Dopamine D2 Receptor AntagonistsDL-dimyristoylphosphatidylglycerol
go.drugbank.com/drugs/DB11284ApprovedDL-dimyristoylphosphatidylglycerol is a phospholipid used in commercially available pharmaceutical preparations to solubilize drugs for injection.
Synonyms: DL-dimyristoylphosphatidylglycerolRibavirin
go.drugbank.com/drugs/DB00811ApprovedInvestigationalas an adjunct therapy to various first-line and second-line combination therapies recommended for each genotypes. … When used to treat Hepatitis C virus (HCV) infections, it is always used as a part of combination therapies as ribavirin monotherapy is not efficacious in the treatment of chronic hepatitis C infection
Synonyms: 1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide, 1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamideMixtures: Rebetron Ready To Use Solution (albumin(human)free) (6000000 Iu/ml and 200mg Capsules)Magnesium oxide
go.drugbank.com/drugs/DB01377ApprovedInvestigationalMagnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. … It is used as an antacid and mild laxative and has many nonmedicinal uses.
Mixtures: L-Methyl PNV DHA, PNV 27-Ca/Fe/FAProducts: Magnesium Oxide HAErdafitinib
go.drugbank.com/drugs/DB12147ApprovedInvestigational[L5956, L5959] Considering urothelial cancer is statistically the fourth most common kind of cancer in the world, the introduction of erdafitinib offers a much-needed new option in the ever-expanding therapeutic … In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index